| The chemotherapy source book MC Perry Lippincott Williams & Wilkins, 2008 | 613 | 2008 |
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib P Jain, M Keating, W Wierda, Z Estrov, A Ferrajoli, N Jain, B George, ... Blood, The Journal of the American Society of Hematology 125 (13), 2062-2067, 2015 | 382 | 2015 |
| Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials K Sasaki, SS Strom, S O'Brien, E Jabbour, F Ravandi, M Konopleva, ... The Lancet Haematology 2 (5), e186-e193, 2015 | 291 | 2015 |
| C hronic lymphocytic leukemia (CLL)—T hen and now KR Rai, P Jain American journal of hematology 91 (3), 330-340, 2016 | 251 | 2016 |
| TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes TM Kadia, P Jain, F Ravandi, G Garcia‐Manero, M Andreef, K Takahashi, ... Cancer 122 (22), 3484-3491, 2016 | 248 | 2016 |
| Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management P Jain, M Wang American journal of hematology 94 (6), 710-725, 2019 | 229 | 2019 |
| Targeted therapy in cancer AM Tsimberidou Cancer chemotherapy and pharmacology 76 (6), 1113-1132, 2015 | 222 | 2015 |
| Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits SK Verma, M Singh, P Jain, A Bordia NISCAIR-CSIR, India, 2004 | 179 | 2004 |
| Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors P Jain, H Kantarjian, KP Patel, GN Gonzalez, R Luthra, RK Shamanna, ... Blood, The Journal of the American Society of Hematology 127 (10), 1269-1275, 2016 | 172 | 2016 |
| Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities P Jain, H Kantarjian, A Nazha, S O’Brien, E Jabbour, CG Romo, S Pierce, ... Blood, The Journal of the American Society of Hematology 121 (24), 4867-4874, 2013 | 168 | 2013 |
| Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes O Benjamini, P Jain, L Trinh, W Qiao, SS Strom, S Lerner, X Wang, ... Leukemia & lymphoma 56 (6), 1643-1650, 2015 | 165 | 2015 |
| Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients P Jain, HM Kantarjian, A Ghorab, K Sasaki, EJ Jabbour, ... Cancer 123 (22), 4391-4402, 2017 | 147 | 2017 |
| Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia XJ Yan, I Dozmorov, W Li, S Yancopoulos, C Sison, M Centola, P Jain, ... Blood, The Journal of the American Society of Hematology 118 (19), 5201-5210, 2011 | 143 | 2011 |
| Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib P Jain, PA Thompson, M Keating, Z Estrov, A Ferrajoli, N Jain, ... Cancer 123 (12), 2268-2273, 2017 | 126 | 2017 |
| Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes GN Tamamyan, HM Kantarjian, J Ning, P Jain, K Sasaki, KL McClain, ... Cancer 122 (18), 2857-2866, 2016 | 122 | 2016 |
| Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study P Jain, H Kantarjian, E Jabbour, GN Gonzalez, G Borthakur, ... The Lancet Haematology 2 (9), e376-e383, 2015 | 110 | 2015 |
| Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs P Jain, H Kantarjian, PC Boddu, GM Nogueras-González, S Verstovsek, ... Blood advances 3 (6), 851-861, 2019 | 108 | 2019 |
| Richter's transformation in chronic lymphocytic leukemia P Jain, S O'Brien Oncology 26 (12), 1146-1146, 2012 | 99 | 2012 |
| Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib P Jain, R Kanagal‐Shamanna, S Zhang, M Ahmed, A Ghorab, L Zhang, ... British Journal of Haematology 183 (4), 578-587, 2018 | 98 | 2018 |
| Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial D Chihara, H Kantarjian, S O'Brien, J Jorgensen, S Pierce, S Faderl, ... British journal of haematology 174 (5), 760-766, 2016 | 98 | 2016 |
